ArticleScientific reports2026
Rational design of cisplatin and carboplatin complexes for enhanced anticancer efficacy based on DFT QTAIM and docking analyses.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cisplatin (CP) and carboplatin (CBP), two key platinum‑based anticancer drugs, face clinical limitations that prompt the search for new strategies to enhance efficacy and reduce toxicity. This study applies density functional theory (DFT), quantum theory of atoms in molecules (QTAIM), molecular docking, and spectroscopic analyses to explore possible synergistic effects of cisplatin-carboplatin [CP-CBP] complexes in breast and cervical cancers. Structural optimizations show small bond‑length adjustments in the [CP-CBP] complexes, which strengthen intermolecular interactions and overall stability. Thermodynamic analyses confirm their exothermic nature (ΔH < 0), indicating thermodynamic stability, while adsorption energies (Ead = - 14.69, - 12.47, - 14.27 kcal/mol for States I, II, III) suggest enhanced bioavailability and controlled release in aqueous environments, though higher gas-phase energies indicate stronger interactions. Quantum descriptors, including electrophilicity index (ω) and chemical potential (μ), reveal increased reactivity and improved drug-target interactions, supporting enhanced anticancer potential. Spectroscopic analyses (UV-Vis, IR) confirm altered electronic transitions, reinforcing stability and reactivity changes. Molecular docking indicates that [CP-CBP] complexes outperform individual CP and CBP, with State III achieving - 3.75 kcal/mol (Ki = 1.78 μM) for aromatase and State II - 5.48 kcal/mol (Ki = 96.86 μM) for HER2. CBP stabilizes CP, preventing degradation, enhancing solubility, and enabling controlled release, reducing toxicity. These findings highlight [CP-CBP] complexes as a promising platinum‑based chemotherapeutic strategy with potentially improved pharmacokinetics, warranting further in vitro and in vivo validation for targeted cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.